12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Scil Technology, Sanofi deal

Scil granted Sanofi exclusive, worldwide rights to a preclinical program for the regenerative treatment of osteoarthritis and cartilage disorders. Scil could receive...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >